TVGN

Tevogen Bio Holdings Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website evogen.com
Employees(FY) 17
ISIN US88165K1016

Performance

-24.87%

-17.44%

+118.46%

+73.17%

-87.24%

YTD

-87.06%

Profile

Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.

Advanced Technical Analysis

Technical Analysis of TVGN 2024-11-20

The stock indicators reflect a mixed sentiment, with the Moving Average Score at 36 indicating a bearish outlook, while the Oscillators Score of 53 suggests a neutral stance, and the overall Technical Score of 45 reinforces a neutral sentiment. This combination implies that while there are some bearish signals, the market is not strongly negativ...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of TVGN

Stock Rank

Recent News & Updates

2024-11-19 03:50
Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model(Globenewswire)
2024-11-14 04:00
UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials(Globenewswire)
2024-11-14 02:49
Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials(Globenewswire)
2024-11-08 02:36
Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations(Globenewswire)
2024-11-05 03:43
Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company's Novel Business Model as Key to Sustainable Success through Patient Affordability(Globenewswire)
2024-11-04 20:27
Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920(Globenewswire)
2024-11-04 01:36
Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support(Globenewswire)
2024-10-30 22:54
Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs(Globenewswire)
2024-10-29 03:28
Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company(Globenewswire)
2024-10-29 02:38
Alpha Capital Appointed as Exclusive Financial Advisor to CD8 Technology to Secure Funding Up To $50 Million(Globenewswire)
2024-10-29 00:43
Tevogen Bio Signs Letter of Intent With CD8 Technology to Build Up to a $50 Million R&D and Manufacturing Facility; No Impact on Shareholder Equity(Globenewswire)
2024-10-25 17:34
Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic Areas(GlobeNewswire)
2024-10-25 05:34
Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic Areas(Globenewswire)
2024-10-23 08:35
Tevogen Bio’s Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug Development(GlobeNewswire)
2024-10-22 20:35
Tevogen Bio's Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug Development(Globenewswire)
2024-10-22 14:30
Tevogen Bio To Provide Timelines Associated with Recently Announced Revenue Forecast and Updates on Operational Readiness This Week(GlobeNewswire)
2024-10-22 02:30
Tevogen Bio To Provide Timelines Associated with Recently Announced Revenue Forecast and Updates on Operational Readiness This Week(Globenewswire)
2024-10-21 15:58
Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion(GlobeNewswire)
2024-10-21 13:56
Tevogen Bio Provides Clarity on CSO Share Sales to Satisfy Tax Obligations, Expects Additional Forecast and Progress Updates in the Coming Days(GlobeNewswire)
2024-10-21 03:58
Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion(Globenewswire)
2024-10-21 01:56
Tevogen Bio Provides Clarity on CSO Share Sales to Satisfy Tax Obligations, Expects Additional Forecast and Progress Updates in the Coming Days(Globenewswire)
2024-10-18 22:46
Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company’s Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming Days(GlobeNewswire)
2024-10-18 10:46
Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company's Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming Days(Globenewswire)
2024-10-17 09:32
Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow(GlobeNewswire)
2024-10-17 07:54
Tevogen Investors Congratulate on Prestigious Recognition of Pioneering Biopharma Business Model, Breakthrough Innovations, Building Assets Estimated to Exceed $10 Billion(GlobeNewswire)
2024-10-16 21:32
Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow(Globenewswire)
2024-10-16 19:54
Tevogen Investors Congratulate on Prestigious Recognition of Pioneering Biopharma Business Model, Breakthrough Innovations, Building Assets Estimated to Exceed $10 Billion(Globenewswire)
2024-10-16 04:30
Tevogen Bio Thanks Warren Township for Proclamation Honoring CEO Dr. Ryan Saadi, Nobel Peace Prize Nomination, and the Company's Mission to Address Health Inequality(Globenewswire)
2024-10-15 02:30
Tevogen Bio Takes Lead in Developing Cell Therapies Designed to Eradicate Post Procedure Human Papilloma Virus in Women with Precancerous Cervical Lesions(Globenewswire)
2024-10-14 23:36
Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company's Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for Immedi(Globenewswire)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.